Rethinking Adoptive Cell Therapy with Novel Bioprocessing Solutions. InteGRAID’s platform is designed to overcome key cell therapy limitations. This is the first device to recapitulate key T cell signals in an ex vivo lymph node structure for T cell activation. InteGRAID provides paracrine delivery of IL-2, avoiding the issue of T cell exhaustion. And InteGRAID's single-use devices reduce Capex/Opex over the entire product life cycle, reducing risk for cross-contamination and labor costs.
Using patent-pending technology developed at Vanderbilt University, our technique overcomes cost and scaleability limitations associated with traditional manufacturing techniques, while also giving commercial viability to carbon conversion technologies through the introduction of a high-value secondary material produced from greenhouse gas inputs. Our technique relies on electrochemistry, rather than solely catalysis, and results in a highly efficient process to convert atmospheric carbon dioxide into useful functional nanomaterials.
Lung cancer is common and often deadly. Accurate diagnosis is key to forming an optimal treatment plan, but pathologists often disagree on diagnosis after visual inspection of patient pathology images. Dr Yu and colleagues have developed a machine-learning technique that processes lung images and makes an accurate and automatic diagnosis.
People with temporomandibular joint osteoarthritis (TMJ OA) experience pain and limited jaw function. Approximately 10 million Americans are affected by TMJ OA, and current treatments are invasive and have high failure rates. Furthermore, palliative treatments aimed at increasing short-term function don't prevent disease or promote regeneration of tissue. StemGEL, WNT Scientifics' solution to this problem, uses fibrocartilage stem cells to regenerate cartilage. They have a paper in Nature Communications (along with several other publications) detailing the successful results. The market size of TMJ OA patients that can be treated by StemGEL is approximately 2.6 million.
While obesity is a growing worldwide epidemic, there are few effective treatments. This technology aims to inhibit a degradation pathway, therefore increasing heat and calorie burn in patients with obesity.
Antimicrobial resistance is emerging as a growing global threat. Currently, more than 10 million people per year become infected by drug-resistant bacteria and those numbers are predicted to grow exponentially in the coming years. There is thus a pressing need for new antibiotics, and in particular for antibiotics with novel mechanisms of action. To address this need we have developed a novel pipeline for rapidly determining the mechanism of action of candidate antibiotics. With this approach we can fundamentally change the traditional antibiotic discovery pipeline by focusing our efforts on compounds with novel mechanisms of action (instead of the traditional efforts that prioritize based on chemical features and efficacy, leading to the rediscovery of similar compounds time and time again).
Cardiac arrhythmias, including atrial fibrillation, put millions of Americans at risk of heart failure or stroke. OptiCardia has a heart visualization system giving the surgeon the ability to assess the effectiveness of Radiofrequency ablation in real time. The technology can result in more effective RF ablation and improve patient outcomes after the procedure.
Osteoporosis affects 50 million Americans and over 200M people worldwide. 50% of hip fracture sufferers lose ability to walk and 20% of suffers dye from it. Over 2M fractures and 300,000 hip fractures occur annually in the U.S. resulting in $20 billion and $12B in annual healthcare expenses, respectively. Currently, greater than 50% of the individuals with osteoporosis are not detected by bone density testing, the standard-of-care diagnostic test. This technology is a high-resolution MRI & CT analysis tool evaluating 3D bone structure and allowing for accurate assessment of (i) bone strength and health, (ii) osteoporosis development risk, and (iii) hip fracture risk. This imaging-based early diagnostic and prognostic for osteoporosis and hip fracture risk has data from over 1000 patients.
AgingSense is a company focused on developing technological solutions to complex problems of aging to improve quality of life of older adults. The first technological solution being developed is Heart Failure Monitoring Socks. This wearable sock technology monitors persons with heart failure for exacerbations as well as response to treatment. The socks monitor for changes related to heart failure specifically, leg edema, using stretch sensors, and fatigue using actigraphy and gyroscopes. Data is sent by blue tooth to an app which is run through an algorithm in a secure cloud that triggers a message to the individual with HF, a trusted other and/or their provider of changes in their condition. The ultimate goal is to improve heart failure management to keep persons with heart failure home and out of the hospital with a better quality of life.
There are 230 million surgeries performed per year worldwide. Surgical experience is the primary factor dictating outcome of each operation. However, surgical experience is not quantifiable, not accessible as a data source, and not easily distributable between users. This leads to variability in outcomes, complications, inefficiency, and high costs in surgical care delivery. What if an artificial intelligence (AI) platform could be designed that would quantify and learn from surgical experience, then customize and distribute tailored information back to all surgeons in real-time?
Graft versus host disease (GVHD) is a severe immune response in patients after transplantation, such as bone marrow transplantation. GvHD is costly to treat and has a high mortality. The current strategy for preventing GvHD include general immuno-suppresent drugs, with limited efficacy and side effects. Therefore, a more targeted approach is needed to prevent GvHD. This technology is a monoclonal antibody which targets cell surface markers on intestinal crypts, which is the primary site of immune attack in GVHD.
Based on engineering research conducted at UC Berkeley, H2Only’s patent-pending technology aims to revolutionize the way we produce water for agriculture. In terms of price point and scale, our technology was designed specifically for our customers: California almond farmers.
Magnets form the core of a wide variety of power electronic devices including motors, inductors and transformers. New magnetic materials are needed to meet the high performance requirements for grid modernization (solid state transformers, PV inductors, sensors); for EVs and aviation (inductors, sensors, motors); and for industrial motor controls (inductors, sensors).
Our goal is to develop a new cancer drug that is an antibody drug conjugate (ADC). It targets the pi subunit of the Gamma Aminobutyric Acid Receptor (GABRP) that is aberrantly expressed in a broad range of solid tumors. The target was discovered by the Pusztai lab and a provisional patent application has been submitted. We will use the Blavatnik Fund to perform affinity maturation, generate humanized anti-GABRP antibody conjugated to emtansine and assess the anti-tumor activity in vitro and in vivo.
Pulmera enables x-ray visualization of the tracheobronchial tree to aid physicians in guiding endoscopic tools in the pulmonary tract. Early diagnosis and treatment are vital for improving lung cancer survival rates, and tissue biopsy is necessary for diagnosis. However, performing a lung biopsy is difficult due to the complexity of the highly branched airways of the lung, making it difficult to access and obtain the tissue and the procedure can pose a risk to the patient. Electromagnetic navigation bronchoscopy (ENB) is the safest way to obtain a biopsy but diagnostic success is limited by poor real time visualization of significant portions of the lung. Should the biopsy procedure be unsuccessful, patients may then need to have the tissue surgically removed. In a high number of these cases, the nodules are found to be benign. Pulmera will greatly improve the ability to obtain a diagnosis for the patient using ENB.
Parallel Works is a web-based platform that simplifies and automates the complex workflow of parallel computing. They speed up simulation and analytics campaigns across industries by making parallel computers from hybrid clouds and clusters easier to use. Their platform is built on the Parsl and Swift parallel scripting technologies developed over the last decade by Argonne National Laboratory, and is designed to run simulation and analytics on the world's largest computing resources.
90% of cancer-related deaths occur due to metastasis. While effective therapies exist to treat primary tumors, treatments to slow/stop metastasis remain ineffective. While immuno-oncology is a new avenue for fighting these metastasized tumors, priming the immune cells has proven difficult. Here, the lab of Prof. King demonstrates a new method to functionalize immune cells. This technology can be applied to metastatic forms of prostate (1.1 million men diagnosed in 2012) and colorectal cancer (1.2 million cases diagnosed in 2015.)
In cosmetic and reconstructive surgeries, surgical mesh is often implanted in order to support the tissue. However, skin-based mesh comes with complications that could result in more than one surgery. DuraSorb is a mesh which pairs the integration potential of skin-based mesh with a decreased risk of complications.
THDG3 represents a novel, patent protected omega-3 diglyceride emulsion developed by Dr. Deckelbaum’s laboratory at Columbia University. Acute injection of THDG3 emulsion following stroke leads to a marked reduction in brain tissue death (up to 90%, demonstrated in 6 rodent models), with associated preservation and recovery of both short and long term neurofunctional outcomes. Due to the high risk profile and short window of administration, less than 8% of stroke patients receive treatment with t-PA, the current standard of treatment for stroke. DeckTherapeutics is currently developing THDG3 emulsion as a drug candidate for standard emergency treatment for stroke, a global unmet need, with phase 2a trials planned in 2021.
Alzheimer's Disease (AD) is a progressive, degenerative disease that is the most common cause of dementia. Brain cell connections and the cells themselves to degenerate and die, eventually destroying memory and other important mental functions. No cure exists, but medications and management strategies may temporarily improve symptoms. An estimated 5.7 million Americans are living with AD in 2018, projected to be 13.8 million by 2050.
PETcoil enables healthcare providers to offer PET/MRI scans with better imaging quality for a fraction of the cost compared to existing solutions. Commercial integrated PET/MRI scanners cost ~$6M + ~$2M for required room renovations, an unaffordable cost for many institutions. PETcoil's patented portable PET insert can be placed into any existing MRI scanner, enabling it to perform simultaneous PET/MRI at 1/8th of the cost compared to integrated systems. A proof-of-concept radiofrequency (RF)-penetrable PET insert has been developed and successfully tested, supported by grants from the NIH, Stanford Bio-X & Biodesign programs, and the Coulter Foundation.
Cancer patients, after the first diagnosis often ask, “how bad is my tumor and what should I do if it is bad?” In about half of all cancer patients, the first line of chemotherapy fails, disease recurs, and patients die. Episteme has succeeded in targeting a specific epigenetic signature of pancreatic cancer patients, which could potentially be reverted by epigenetic drugs making the tumors amenable to chemotherapy. Episteme invented a novel microarray-based platform technology called “ATAC-Array”. This proprietary technology avoids the time and cost of next-generation ATAC library sequencing – the only microarray that reads chromatin accessibility. No other test provides such a comprehensive, cost-effective and clinically useful epigenetic summary. Episteme offers a personalized theragnostic test utilizing ATAC-array, histopathology and immunohistochemistry, to predict chemotherapy response and stratifying cancer patients to epigenetic (reprograming) therapy for better outcome and better quality of life.
Gold mining has been a historically low innovation industry. The industry standard is to use a cyanide process to isolate gold, which is expensive and potentially dangerous. Cycladex has created a method to isolate gold in an inexpensive, environmentally-friendly way.
MAEGI is a new class of immunotherapy which activates a customizable group of genes for personalized cancer treatment. It can be used as an off the shelf cancer treatment or a highly customized treatment specific to certain cancer types or patients.
Between 2007 and 2017, there has been a 377% increase in the treatment of diagnosed anaphylactic reactions to food. The current standard of care is not enough to stem the tide of patients suffering the healthcare costs of food allergies. Phlaxis is an innovative immune tolerance company focused on providing a new approach to treating food allergies. Phalxis' allergen tolerance platform features proteins, or antigens, that are engineered to deliver precise, targeted allergy therapy, without the side effects of broad immunosuppression. Phalxis’ allergen-specific platform can be translated to virtually any food allergy, including the Big 8 of milk, eggs, peanuts, tree nuts, fish, crustacean shellfish, wheat, and soy.
In the future, the power grid will be a large-scale network of distributed energy resources (DERs), each introducing random and rapid fluctuations in power supply, demand, voltage and frequency. These DERs provide tremendous opportunity for sustainability, efficiency, and power reliability. However, a major issue is how intelligent devices and independent producers can achieve maximum and reliable efficiency for the power network. Singularity's hardware-agnostic algorithmic platform can provide the intelligent control for the smart grid of the future.
Evolution-Proof Therapy Against Multi-Drug Resistant Bacterial Pathogens with Efflux Pump-Targeting Phage. Multi-drug resistant (MDR) Pseudomonas aeruginosa is a common pathogen in the lungs of those with cystic fibrosis. These infections are notoriously difficult to manage and new approaches to control them are desperately needed. Based on our prior therapeutic success treating lung infections with virulence and resistance targeting bacteriophage, we plan to expand our patient population and perform a small clinical trial at Yale-New Haven Hospital examining the safety and preliminary effectiveness of phage therapy to treat lung infections in those with cystic fibrosis. Received Blavatnik Awards in May 2018 and May 2019.
LEGIT uses a new optical concept (a lensguide) developed at Columbia University to improve optical endoscopy. Their goal is the development of a whole microscopy probe (size ~ 0.1-1 mm) that can be inserted in the body, with minimal damage, for high resolution imaging (<1 µm resolution). The LEGIT endoscopic probe can be used for cancer diagnostics (e.g. skin and liver cancer) and in vivo biopsy imaging. The LEGIT lensguide is a higher quality and less expensive replacement for the GRIN lenses with significantly higher flexibility in design and manufacturing.
A vast majority of drugs and biologics fail to enter the brain for treatment of brain cancers and neurological diseases. Our discovery yielded key insights into how the immune system naturally overcomes the blood brain barrier to fight infections. We leverage this insight to enable safe and transient drug access to the CNS using a simple intranasal peptide delivery approach.
Cysteine protease enzymes are widely used in a range of chemical manufacturing applications. A naturally found amino acid selenocysteine increases activity of cysteine protease enzymes when subsituted for cysteine. Sec-U-Lar is utilizing this property to substitute selenocysteine in cysteine protease enzymes, increasing their activity more than 100-fold.
As part of a portfolio of COVID-19 inspired innovations aimed at advancing RNA vaccines and tools, Stanford researchers have developed a secured, invite-only version of their popular Eterna platform for designing mRNA vaccines. Eterna is an online application that integrates RNA folding algorithms, a video game interface, and associated computational methods to revolutionize vaccine design and RNA structure prediction. The new, secured version of the platform (called EteRNA Enterprise) is able to host selected participants to work in a confidential manner on problems such as designing improved mRNA vaccines that can be translated to clinical trials by industry partners and other collaborators. The data and designs generated by Eterna users may be used to develop improved mRNA vaccines immediately for the COVID-19 pandemic.
Patients who undergo life-saving cardiac procedures (such as aortic valve replacement) are often exposed to a related harm: stroke, infarction, and brain injury. These strokes are due to the release of emboli, or particulate material such as a plaque, that travel in the blood from the heart to the brain during surgery. In response to a growing body of evidence of this problem, Lifeguard is a neuro-protective device that provides coverage to all three aortic arch takeoffs. Lifeguard is led by Yale Professor of Medicine Dr. Alexandra Lansky and Yale Associate Professor of Biomedical Engineering Dr. Tarek Fahmy.
While deep learning methods exist to guide protein optimization, examples of novel proteins generated with these techniques require a priori mutational data. Aperiam is taking the guesswork out of biotechnology with computer vision that illuminates critical parts of protein chemistry. We have trained a portfolio of computer vision algorithms on protein chemistry and use those algorithms to mutate genes for improved catalysis, expression, stability, and solubility. We are now using this approach to build our own suite of stabilized and solubilized enzyme therapeutics for direct delivery to the lung via nebulization and in parallel tailoring the computer vision framework to antibodies for expedited development and improved manufacturability.
We have applied a unique, robust, and comprehensive image-based assay developed in our laboratory to discover small molecule inhibitors of nucleolar function. Results from pilot screens on FDA-approved drugs reveal 83 unique hits that include known and putative antineoplastic agents.
1 in 400 Americans carry a breast cancer gene (BRCA) mutation - such a mutation increases the likelihood of developing breast cancer from 12 to ~70% by age 80, and raises the lifetime risk of ovarian cancer from 1.3% to 44% (BRCA1) or 17% (BRCA2). Additionally, men with BRCA1 or BRCA2 mutations are also at increased risk for breast and prostrate cancers, and both men and women with either mutation are at an increased risk of pancreatic cancer. BRCA proteins are essential for DNA repair, making BRCA-deficient cells (i.e. those with a BRCA mutation) susceptible to synthetic lethality and providing an opportunity to kill cancers with the mutation. PARP-inhibitors invoke synthetic lethality to kill BRCA-mutated cells via PARP-trapped lesions, however cells can become resistant to this mode of therapy, creating an unmet clinical need for these cancers. Indeed, nearly 300,000 new cases of breast or ovarian cancer will be diagnosed in 2019, making the need for an improved synthetic lethality agent urgent.
Folic acid supplements are used for preventing severe birth defects by maintaining the DNA integrity in the developing embryo. This technology describes two downstream metabolites of folic acid, one of which is an effective replacement for folic acid as a prenatal supplement, more directly impacting nucleotide synthesis. The other is a oral therapy for cancer, which has demonstrated prevention of tumor development in mouse models.
Despite it being a rare disease, pulmonary arterial hypertension (PAH) is a costly and deadly condition of the pulmonary artery. Verso therapeutics is pursuing an HDAC inhibitor as a treatment for PAH which restores normal pulmonary vasculature unlike existing treatments which fail to address the abnormal architecture.
A Novel Platform to Develop piRNA-Based Therapeutics for Cancer Treatment. PIWI-interacting RNAs (piRNAs) is a novel pathway for nucleic acid based targeted therapy. piRNAs consist of small non-coding RNAs that interact with PIWI proteins. The PIWI/piRNA pathway protects the genome from destabilizing transposon activity by using piRNA to guide PIWI proteins to transposable genome sites, leading to gene specific methylation in somatic cells. piRNAs offer potential advantages because the longer piRNA seed sequences results in higher target specificity, higher tissue specificity, higher efficacy, and lower toxicity over siRNA and miRNA techniques. Short-term focus is currently on treating liver cancer because of the relative ease of drug delivery and lack of effective treatments.
There are over 900k cocaine addicts in the USA alone while worldwide cocaine usage rates have been growing at over 2% a year over the last decade. In the USA this results in over 15k deaths, 505k ER visits and $21B lost annually. Despite all of this, there is currently no FDA approved treatment for cocaine abuse disorder. AddGraft Therapeutics aims to be the first FDA approved treatment for cocaine abuse disorder utilizing our revolutionary gene delivery platform. Our treatment promises to be long lasting, minimally invasive and highly effective at treating the challenging aspects of addiction. AddGraft's technology is a novel skin-based gene delivery platform for treating cocaine abuse. Patients receive an autologous skin graft of genetically modified skin-stem cells which produces a dual molecule solution to effectively break down cocaine, preventing lethal overdose, and to behaviorally prevent frequent use, relapse, and developing of new addictive behaviors.
Working men and women lift every day. They do it in warehouses and on production lines. In offices and combat zones. Every day, they lift the economy worldwide. Whether it’s the day-to-day grind or responding to a crisis, their strength supports us all. And they deserve gear that sustains their strength, for work and for life. That makes their job safer. The HeroWear Apex means that their weight is over. The world’s first exosuit for all, built from the ground up for both men and women, the Apex is a back-assist exosuit that uses a proprietary band-based mechanism to reduce strain on the back without getting in the way.
Aero Therapeutics is helping physicians in low-resource settings treat neonatal respiratory issues with their sustainable, rugged and affordable devices. Their current device oxygenates, warms, humidifies, and sterilizes air before it is delivered in a single, compact, and mobile enclosure. Developed iteratively in Ethiopia, their final prototype demonstrates comparable performance with commercially available devices at ~1/10th the cost.
We have developed a novel linker technology that can enable potent targeting of nanomedicines for therapeutic and diagnostic applications. We further have a unique clinical pipeline for development of this technology using ex vivo perfusion of non-transplanted human organs. Our primary lab, the Tietjen lab, has developed a robust pipeline for preclinical research on human kidney and liver with the capacity to expand to heart and lung in the future. This provides a direct path to clinical impact in organ transplantation and will enable broad translation for a variety of indications.
The human immune system participates in complex interactions with virtually all other systems in the body. In particular, the B-cell component of the adaptive immune response plays a role in various disease settings, including infectious disease, cancer, autoimmunity, cardiovascular, hematologic, neurologic diseases, and others. In addition, antibodies (a product of B cells) are effectively used in diagnostics, therapy, and prevention. To address these significant challenges with current technologies for B cell characterization and antibody discovery, we recently developed a novel technology that, for a given sample, enables the mapping of antibody sequence to antigen specificity from a single high-throughput experiment for a large number of antigens and B cells at a time.
This 3D printing technology (“Hybprinter”) can be used to form hybrid multi-material constructs incorporating a wide spectrum of materials (rigid and soft) and bioagents (such as cells and growth factors) with controlled spatial distribution in any XYZ coordinate across the hybrid structure. There are several technologies available to perform 3D bioprinting However, the main disadvantage is that only one type of material can be printed by many of these methods. However, due to its layer-by-layer manufacturing nature, Hybprinter enables the combination of cell-laden soft and hard biomaterials with a controlled spatial distribution for regenerative medicine applications.
KIN-Therapeutics is developing an AI-based computational platform integrating structural bioinformatics and machine learning with experimental approaches to identify small molecules targeting specific protein kinase targets and conformations. The Kinase Inhibitor (KIN) artificial intelligence (AI) is able to generate de novo kinase drugs with optimal selectivity. This technology will allow for better design and discovery of clinically relevant kinase inhibitors, which will have significant implications for cancer, Alzheimer’s disease, and even diabetes treatments. KIN focuses on a manageable and clinically-relevant chemical space and is entering into a partnership with a biotech company to design conformation specific immune-oncology inhibitors. KIN is looking for a CEO / Chair of the Board to lead the next steps for the venture.
There is a growing aging population and there is no cure or treatment for Alzheimer's. The only current drugs are palliative. The Synapse Enhancer enhances the integrity of the synapse which improves cognitive function and can delay/halt neurodegeneration. It could be utilized for a many diseases such as, Alzheimer's, ALS, Parkinson's, Huntington's, Traumatic Brain Injury, Stroke, Epilepsy, Depression, Neuropathic Pain Disorders, and Addiction.
Our data shows via genetic and pharmacological studies that the Ire1alpha-XBP1 pathway is a novel genetic interactor of Pkd1 and can strongly modulate the progression of ADPKD in murine models by protecting Pkd1 kidney cyst cells from apoptosis without impacting their proliferation. Tilting the balance from low to high apoptosis levels (via inactivation of XBP1 on a Pkd1 KO background) given similar proliferation profiles may thus provide a viable therapeutic option in the context of cystic kidney disease. Given that the target pathway in this case is very well characterized and not needed for kidney development or homeostasis, our data offers a potentially exciting therapeutic option for slowing down ADPKD (and possibly ARPKD) by targeting Ire1alpha-XBP1. Furthermore, we have identified a potent agent that leads to a dramatic decrease in polycystic kidney disease progression in both early and adult mouse models. This agent represents a promising candidate for further pre-clinical/clinical development.
ProteoWise was founded by a seasoned team of scientists from the Strittmatter Laboratory at Yale University which has a history of commercialization of innovations emerging from the lab. ProteoWise aims to unlock the protein world. Its technology will disrupt the protein analysis industry by enabling researchers to move beyond the current Western Blot standard and into easy, high-throughput bench-top proteomics.
Conventional electronic devices based on flexible or rigid printed circuit boards (PCBs) cannot conform to curved surfaces or stretch to accommodate new requirements of disruptive technologies. Additionally, existing methods for the production of stretchable electronics are unable to produce devices with high integration densities achievable with conventional methods. These methods also rely on processes that cannot be implemented at scale. This technology overcomes these limitations and enables practical applications of stretchable electronic devices for health monitoring, wearable computing, medical devices, and beyond.
Kayothera is leveraging cutting-edge discoveries to develop therapeutics for cancer patients who currently receive terminal diagnoses. Our two pipeline candidates target solid tumors to 1) inhibit tumor survival mechanisms in advanced or chemoresistant disease, 2) deplete immunosuppressive Regulatory T cells to restore anti-tumor immunity. With these first-in-class small molecule therapeutics, we aim to give hope to patients with intractable cancers.